Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb open-label multicenter study of B1962 injection in advanced colorectal cancer
CTR20244941Phase 2Active
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Start
- Dec 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of B1962 in colorectal cancer (CRC) (2 arms), sponsored by Tasly Biopharmaceuticals Co., Ltd. Primary endpoint: Objective response rate. Started Dec 2024; status: active.
02
Drugs
B1962
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20244941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244941.